PDF(Pubmed)
Abstract：
UNASSIGNED: Immune checkpoint inhibitors (ICIs) represent a groundbreaking approach to cancer therapy. Inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) have emerged as potential indicators strongly associated with tumor prognosis, albeit their prognostic significance remains contentious. The predictive value of NLR, PLR, LMR in patients with gastric cancer (GC) treated with ICIs has not been fully explored; therefore, we conducted a meta-analysis to examine the potential of inflammatory markers NLR, PLR, and LMR as survival predictors in this population.
UNASSIGNED: A comprehensive search was conducted across PubMed, Embase, Web of Science, and Cochrane databases, with the search cut-off date set as March 2024. Hazard ratios (HR) and their corresponding 95% confidence intervals (CI) were calculated to assess the prognostic significance of NLR, PLR, and LMR for both progression-free survival (PFS) and overall survival (OS).
UNASSIGNED: Fifteen cohort studies involving 1336 gastric cancer patients were finally included in this meta-analysis. The results of the meta-analysis showed that high levels of NLR were associated with poorer OS and PFS in GC patients receiving ICIs, with combined HRs of OS [HR=2.01, 95%CI (1.72,2.34), P<0.01], and PFS PFS[HR=1.59, 95%CI (1.37,1.86), P<0.01], respectively; high levels of PLR were associated with poorer OS and PFS, and the combined HR was OS [HR=1.57, 95%CI (1.25,1.96), P<0.01], PFS [HR=1.52,95%CI (1.20, 1.94), P<0.01], respectively; and there was an association between elevated LMR and prolonged OS and PFS, and the combined HR was OS [HR=0.62, 95%CI (0.47,0.81), P<0.01], and PFS [HR=0.69, 95%CI (0.50,0.95), P<0.01].
UNASSIGNED: In gastric cancer (GC) patients treated with immune checkpoint inhibitors (ICIs), elevated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with poorer overall survival (OS) and progression-free survival (PFS), while high lymphocyte-to-monocyte ratio (LMR) was linked to improved OS and PFS. Subgroup analyses suggested that NLR might be particularly pertinent to the prognosis of GC patients. In conclusion, the inflammatory markers NLR, PLR, and LMR serve as effective biomarkers for prognostic assessment in GC patients, offering valuable insights for therapeutic decision-making in the realm of GC immunotherapy. Prospective studies of high quality are eagerly awaited to validate these findings in the future.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO/#myprospero, identifier CRD42024524321.
UNASSIGNED: A comprehensive search was conducted across PubMed, Embase, Web of Science, and Cochrane databases, with the search cut-off date set as March 2024. Hazard ratios (HR) and their corresponding 95% confidence intervals (CI) were calculated to assess the prognostic significance of NLR, PLR, and LMR for both progression-free survival (PFS) and overall survival (OS).
UNASSIGNED: Fifteen cohort studies involving 1336 gastric cancer patients were finally included in this meta-analysis. The results of the meta-analysis showed that high levels of NLR were associated with poorer OS and PFS in GC patients receiving ICIs, with combined HRs of OS [HR=2.01, 95%CI (1.72,2.34), P<0.01], and PFS PFS[HR=1.59, 95%CI (1.37,1.86), P<0.01], respectively; high levels of PLR were associated with poorer OS and PFS, and the combined HR was OS [HR=1.57, 95%CI (1.25,1.96), P<0.01], PFS [HR=1.52,95%CI (1.20, 1.94), P<0.01], respectively; and there was an association between elevated LMR and prolonged OS and PFS, and the combined HR was OS [HR=0.62, 95%CI (0.47,0.81), P<0.01], and PFS [HR=0.69, 95%CI (0.50,0.95), P<0.01].
UNASSIGNED: In gastric cancer (GC) patients treated with immune checkpoint inhibitors (ICIs), elevated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with poorer overall survival (OS) and progression-free survival (PFS), while high lymphocyte-to-monocyte ratio (LMR) was linked to improved OS and PFS. Subgroup analyses suggested that NLR might be particularly pertinent to the prognosis of GC patients. In conclusion, the inflammatory markers NLR, PLR, and LMR serve as effective biomarkers for prognostic assessment in GC patients, offering valuable insights for therapeutic decision-making in the realm of GC immunotherapy. Prospective studies of high quality are eagerly awaited to validate these findings in the future.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO/#myprospero, identifier CRD42024524321.
摘要：
■免疫检查点抑制剂（ICIs）代表了一种开创性的癌症治疗方法。炎症标志物，如中性粒细胞与淋巴细胞比率（NLR），血小板与淋巴细胞比率（PLR），淋巴细胞与单核细胞比率（LMR）已成为与肿瘤预后密切相关的潜在指标，尽管它们的预后意义仍然存在争议。NLR的预测价值，PLR,用ICI治疗的胃癌（GC）患者的LMR尚未得到充分探索；因此，我们进行了一项荟萃分析，以检查炎症标志物NLR的潜力，PLR,和LMR作为该人群的生存预测因子。
■对PubMed进行了全面搜索，Embase,WebofScience,和Cochrane数据库，搜索截止日期为2024年3月。计算危险比（HR）及其相应的95％置信区间（CI）以评估NLR的预后意义。PLR,和LMR用于无进展生存期（PFS）和总生存期（OS）。
■15项涉及1336例胃癌患者的队列研究最终纳入本荟萃分析。荟萃分析结果显示，在接受ICIs的GC患者中，高水平的NLR与较差的OS和PFS相关。OS的合并HR[HR=2.01，95CI（1.72,2.34），P<0.01],和PFSPFS[HR=1.59，95CI（1.37,1.86），P<0.01],分别；高水平的PLR与较差的OS和PFS相关，合并的HR为OS[HR=1.57，95CI（1.25，1.96），P<0.01],PFS[HR=1.52,95CI（1.20，1.94），P<0.01],分别；LMR升高与OS和PFS延长之间存在关联，合并的HR为OS[HR=0.62，95CI（0.47，0.81），P<0.01],和PFS[HR=0.69，95CI（0.50，0.95），P<0.01]。
■在接受免疫检查点抑制剂（ICIs）治疗的胃癌（GC）患者中，中性粒细胞与淋巴细胞比率（NLR）和血小板与淋巴细胞比率（PLR）升高与总生存期（OS）和无进展生存期（PFS）较差相关，而高淋巴细胞与单核细胞比率（LMR）与改善的OS和PFS有关。亚组分析表明，NLR可能与GC患者的预后特别相关。总之,炎症标志物NLR，PLR,和LMR作为GC患者预后评估的有效生物标志物，为GC免疫治疗领域的治疗决策提供有价值的见解。人们热切地期待着高质量的前瞻性研究，以在未来验证这些发现。
■https://www.crd.约克。AC.uk/PROSPERO/#myprospro,标识符CRD42024524321。
■对PubMed进行了全面搜索，Embase,WebofScience,和Cochrane数据库，搜索截止日期为2024年3月。计算危险比（HR）及其相应的95％置信区间（CI）以评估NLR的预后意义。PLR,和LMR用于无进展生存期（PFS）和总生存期（OS）。
■15项涉及1336例胃癌患者的队列研究最终纳入本荟萃分析。荟萃分析结果显示，在接受ICIs的GC患者中，高水平的NLR与较差的OS和PFS相关。OS的合并HR[HR=2.01，95CI（1.72,2.34），P<0.01],和PFSPFS[HR=1.59，95CI（1.37,1.86），P<0.01],分别；高水平的PLR与较差的OS和PFS相关，合并的HR为OS[HR=1.57，95CI（1.25，1.96），P<0.01],PFS[HR=1.52,95CI（1.20，1.94），P<0.01],分别；LMR升高与OS和PFS延长之间存在关联，合并的HR为OS[HR=0.62，95CI（0.47，0.81），P<0.01],和PFS[HR=0.69，95CI（0.50，0.95），P<0.01]。
■在接受免疫检查点抑制剂（ICIs）治疗的胃癌（GC）患者中，中性粒细胞与淋巴细胞比率（NLR）和血小板与淋巴细胞比率（PLR）升高与总生存期（OS）和无进展生存期（PFS）较差相关，而高淋巴细胞与单核细胞比率（LMR）与改善的OS和PFS有关。亚组分析表明，NLR可能与GC患者的预后特别相关。总之,炎症标志物NLR，PLR,和LMR作为GC患者预后评估的有效生物标志物，为GC免疫治疗领域的治疗决策提供有价值的见解。人们热切地期待着高质量的前瞻性研究，以在未来验证这些发现。
■https://www.crd.约克。AC.uk/PROSPERO/#myprospro,标识符CRD42024524321。
